On March 1, 2019, Novartis sued Johnson & Johnson subsidiary Janssen for allegedly presenting false and misleading data about its plaque psoriasis drug Tremfya® (guselkumab). Novartis alleges that its Cosentyx® (secukinumab) drug, which is also indicated for the treatment of plaque psoriasis, competes with Tremfya®. Novartis claims that Janssen failed to present key safety information, and “cherry-pick[ed]” the adverse events that it reported in marketing materials, in violation of the Lanham Act, 15 U.S.C. §§ 1125(a). Novartis also sought a temporary restraining order, which the court denied. The court set today as the deadline for Novartis’s revised preliminary injunction motion, with Janssen’s response due March 7 and Novartis’s reply due March 8.